Preferred Label : larotrectinib;

CISMeF synonym : ARRY-470;

MeSH synonym : (3S)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;

MeSH hyponym : BAY2757556; LOXO101; ARRY470;

UNII : PF9462I9HX;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3422863/fr/vitrakvi-larotrectinib-fibrosarcome-infantile-et-autres-sarcomes-pediatriques-des-tissus-mous
2023
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
administration, oral
capsules
pharmaceutical solutions
sarcoma
Refractory Childhood Soft Tissue Sarcoma
Metastatic Childhood Soft Tissue Sarcoma
Recurrent Childhood Soft Tissue Sarcoma
Infantile Fibrosarcoma
protein kinase inhibitors
larotrectinib
TRK Receptor Family Fusion Positive
evaluation of the transparency committee
larotrectinib
fibrosarcoma

---
https://www.has-sante.fr/jcms/p_3290908/fr/vitrakvi-20-mg/ml-larotrectinib
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
evaluation of the transparency committee
administration, oral
pharmaceutical solutions
larotrectinib
larotrectinib
child
fibrosarcoma
Infantile Fibrosarcoma
sarcoma
Refractory Soft Tissue Sarcoma
Recurrent Soft Tissue Sarcoma
Metastatic Soft Tissue Sarcoma
Locally Advanced Soft Tissue Sarcoma
Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion (disorder)

---
https://www.has-sante.fr/jcms/p_3193768/fr/vitrakvi
2020
false
false
false
France
larotrectinib
insurance, health, reimbursement
child
Infantile Fibrosarcoma
fibrosarcoma
sarcoma
neoplasm metastasis
treatment outcome
adult
administration, oral
protein kinase inhibitors
Product containing only larotrectinib in oral dose form (medicinal product form)
evaluation of the transparency committee
larotrectinib
pyrazoles
pyrimidines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
antineoplastic agents
antineoplastic agents
administration, oral
adult
neoplasms
neoplasms
product surveillance, postmarketing
child
gene fusion
receptor, trka
receptor, trkb
receptor, trkc
adolescent
aged
drug interactions
pregnancy
breast feeding
receptor, trka
receptor, trkb
receptor, trkc
protein kinase inhibitors
protein kinase inhibitors
drug evaluation, preclinical
larotrectinib
Tyrosine Kinase Inhibitors
larotrectinib
larotrectinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines

---
Nous contacter.
10/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.